Incorporating progesterone receptor expression into the PREDICT Breast prognostic model

Isabelle Grootes1, Renske Keeman2, Fiona M Blows1, Roger L. Milne3,5, Graham G. Giles3,5, Anthony J. Swerdlow6,7, Peter A. Fasching8,9, Mustapha Abubakar10, Irene L. Andrulis11,12, Hoda Anton-Culver13, Matthias W. Beckmann9, Carl Blomqvist14,15, Stig E. Bojesen16,18, Manjeet K. Bolla19, Bernardo Bonanni20, Ignacio Briceno21, Barbara Burwinkel22,23, Nicola J. Camp24, Jose E. Castelao25, Ji-Yeob Choi26,28, Christine L. Clarke29, Fergus J. Couch30, Angela Cox31, Simon S. Cross32, Kamila Czene33, Peter Devilee34,35, Thilo Dörk36, Alison M. Dunning3, Miriam Dwek37, Douglas F. Easton1,19, Diana M. Eccles38, Mikael Eriksson33, Kristina Ernst39, D. Gareth Evans40,41, Jonine D. Figueroa42,43, Visnja Fink39, Giuseppe Floris44, Stephen Fox45, Marike Gabrielson33, Manuela Gago-Dominguez46,47, José A. García-Sáenz48, Anna González-Neira49, Lothar Haeberle5, Christopher A. Haiman50, Per Hall51,52, Ute Hamann52, Elaine F. Harkness53,55, Mikael Hartman56,57, Alexander Hein5, Maartje J. Hooning58, Ming-Feng Hou59, Sacha J. Howell60, ABCTB Investigators61, kConFab Investigators62,63, Hidemi Ito64,65, Anna Jakubowska66,67, Wolfgang Janni39, Esther M. John68,69, Audrey Jung70, Dahee Kang71,72, Vessela N. Kristensen72,73, Ava Kwong74,75, Diether Lambrechts77,78, Jingmei Li79, Jan Lubirski66, Mehdi Manoochehri52, Sara Margolin51,80, Keitaro Matsuo85,81, Nur Aishah Mohd Taib92, Anna Marie Mulligan83,84, Heli Nevanlinna85, William G. Newman40,41, Kenneth Offit86,87, Anna Osorio88,89, Sue K. Park90,91,92, Tjoung-Won Park-Simon26, Alpa V. Patel90, Nadege Presneau37, Katri Pylkäs91,92, Brigitte Rack39, Paolo Radice93, Gad Rennert94, Atocha Romero95, Emmanouil Saloustros96, Elinor J. Sawyer97, Andreas Schneevoss23,98, Fabienne Schochter39, Minouk J. Schoemaker6, Chen-Yang Shen99,100, Rana Shibli94, Peter Sinn101, William J. Tapper18, Essa Tawfiq102, Soo Hwang Teo102,103, Lauren R. Teras90, Diana Torres52,104, Celine M. Vachon105, Carolien H.M. van Deurzen106, Camilla Wendt60, Justin A. Williams102, Robert Winqvist91,92, Mark Elwood102, Marjanka K. Schmidt2,107, Montserrat García-Closas10, Paul D.P. Pharaoah1,19.

Key words: Prognosis, PREDICT, breast cancer, progesterone receptor

1 University of Cambridge, Centre for Cancer Genetic Epidemiology, Department of Oncology, Cambridge, UK, CB1 8RN.
2 The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Division of Molecular Pathology, Amsterdam, The Netherlands, 1066 CX.
3 Cancer Council Victoria, Cancer Epidemiology Division, Melbourne, Victoria, Australia, 3004.
4 The University of Melbourne, Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, Melbourne, Victoria, Australia, 3101.
5 Monash University, Precision Medicine, School of Clinical Sciences at Monash Health, Clayton, Victoria, Australia, 3168.
6 The Institute of Cancer Research, Division of Genetics and Epidemiology, London, UK, SM2 5NG.
7 The Institute of Cancer Research, Division of Breast Cancer Research, London, UK, SW7 3RP.
8 University of California at Los Angeles, David Geffen School of Medicine, Department of Medicine Division of Hematology and Oncology, Los Angeles, CA, USA, 90095.
9 Comprehensive Cancer Center Erlangen-EMN, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg (FAU), Department of Gynecology and Obstetrics, Erlangen, Germany, 91054.
10 National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Division of Cancer Epidemiology and Genetics, Bethesda, MD, USA, 20850.
11 Lunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital, Fred A. Litwin Center for Cancer Genetics, Toronto, ON, Canada, M5G 1X5.
12 University of Toronto, Department of Molecular Genetics, Toronto, ON, Canada, M5S 1A8.
13 University of California Irvine, Department of Medicine, Genetic Epidemiology Research Institute, Irvine, CA, USA, 92617.
14 University of Helsinki, Department of Oncology, Helsinki University Hospital, Helsinki, Finland, 00290.
15 ...rebro University Hospital, Department of Oncology, ...rebro, Sweden, 70185.

1
Copenhagen University Hospital, Copenhagen General Population Study, Herlev and Gentofte Hospital, Herlev, Denmark, 2730.
17 Copenhagen University Hospital, Department of Clinical Biochemistry, Herlev and Gentofte Hospital, Herlev, Denmark, 2730.
18 University of Copenhagen, Faculty of Health and Medical Sciences, Copenhagen, Denmark, 2200.
19 University of Cambridge, Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, Cambridge, UK, CB1 8RN.
20 IEO, European Institute of Oncology IRCCS, Division of Cancer Prevention and Genetics, Milan, Italy, 20141.
21 Universidad de La Sabana, Medical Faculty, Bogota, Colombia, 140013.
22 German Cancer Research Center (DKFZ), Molecular Epidemiology Group, CO80, Heidelberg, Germany, 69120.
23 University of Heidelberg, Molecular Biology of Breast Cancer, University Womens Clinic Heidelberg, Heidelberg, Germany, 69120.
24 University of Utah, Department of Internal Medicine and Huntsman Cancer Institute, Salt Lake City, UT, USA, 84112.
25 Instituto de Investigación—n Sanitaria—Galicia Sur (IIISGS), Xerencia de Xestión Integrada de Vigo-SERGAS, Oncology and Genetics Unit, Vigo, Spain, 36312.
26 Seoul National University Graduate School, Department of Biomedical Sciences, Seoul, Korea, 03080.
27 Seoul National University, Cancer Research Institute, Seoul, Korea, 03080.
28 Seoul National University Medical Research Center, Institute of Health Policy and Management, Seoul, Korea, 03080.
29 University of Sydney, Westmead Institute for Medical Research, Sydney, New South Wales, Australia, 2145.
30 Mayo Clinic, Department of Laboratory Medicine and Pathology, Rochester, MN, USA, 55905.
31 University of Sheffield, Sheffield Institute for Nucleic Acids (SInFoNiA), Department of Oncology and Metabolism, Sheffield, UK, S10 2TN.
32 University of Sheffield, Academic Unit of Pathology, Department of Neuroscience, Sheffield, UK, S10 2TN.
33 Karolinska Institutet, Department of Medical Epidemiology and Biostatistics, Stockholm, Sweden, 171 65.
34 Leiden University Medical Center, Department of Pathology, Leiden, The Netherlands, 2333 ZA.
35 Leiden University Medical Center, Department of Human Genetics, Leiden, The Netherlands, 2333 ZA.
36 Hannover Medical School, Gynaecology Research Unit, Hannover, Germany, 30625.
37 University of Westminster, School of Life Sciences, London, UK, W1B 2HW.
38 University of Southampton, Faculty of Medicine, Southampton, UK, SO17 1BJ.
39 University Hospital Ulm, Department of Gynaecology and Obstetrics, Ulm, Germany, 89075.
40 University of Manchester, Manchester Academic Health Science Centre, Division of Evolution and Genomic Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, Manchester, UK, M13 9WL.
41 St MaryÕs Hospital, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, North West Genomics Laboratory Hub, Manchester Centre for Genomic Medicine, Manchester, UK, M13 9WL.
42 The University of Edinburgh, Usher Institute of Population Health Sciences and Informatics, Edinburgh, UK, EH16 4UX.
43 The University of Edinburgh, Cancer Research UK Edinburgh Centre, Edinburgh, UK, EH4 2XR.
44 Leuven Cancer Institute, University Hospitals Leuven, Leuven Multidisciplinary Breast Center, Department of Oncology, Leuven, Belgium, 3000.
45 Peter MacCallum Cancer Center, Melbourne, Victoria, Australia, 3000.
46 Instituto de Investigación—n Sanitaria de Santiago de Compostela (IDIS), Compléxio Hospitalario Universitario de Santiago, SERGAS, Fundación—n Pæblica Galega de Medicina Xen¡mica, Santiago de Compostela, Spain, 15706.
47 University of California San Diego, Moores Cancer Center, La Jolla, CA, USA, 92037.
48 Instituto de Investigación—n Sanitaria San Carlos (IdISSC), Centro Investigación—n Biomédica en Red de Cáncer (CIBERONC), Medical Oncology Department, Hospital Clínicas San Carlos, Madrid, Spain, 28040.
49 Spanish National Cancer Research Centre (CNIO), Human Cancer Genetics Programme, Madrid, Spain, 28029.
50 University of Southern California, Department of Preventive Medicine, Keck School of Medicine, Los Angeles, CA, USA, 90033.
Correspondence: Isabelle Grootes

Department of Oncology,
University of Cambridge, Strangeways Research Laboratory,
Cambridge, CN1 8RN, United Kingdom

Email: ig345@medschl.cam.ac.uk
Tel: +44 (0) 1223 761949
Funding:

BCAC is funded by the European Union’s Horizon 2020 Research and Innovation Programme (grant numbers 634935 and 633784 for BRIDGES and B-CAST respectively), and the PERSPECTIVE I&I project, funded by the Government of Canada through Genome Canada and the Canadian Institutes of Health Research, the Ministère de l’Économie et de l’Innovation du Québec through Genome Québec, the Quebec Breast Cancer Foundation. The EU Horizon 2020 Research and Innovation Programme funding source had no role in study design, data collection, data analysis, data interpretation or writing of the report. Additional funding for BCAC is provided via the Confluence project which is funded with intramural funds from the National Cancer Institute Intramural Research Program, National Institutes of Health.

The ABCS study was supported by the Dutch Cancer Society [grants NKI 2007-3839; 2009 4363]. The Australian Breast Cancer Tissue Bank (ABCTB) was supported by the National Health and Medical Research Council of Australia, The Cancer Institute NSW and the National Breast Cancer Foundation. The work of the BBCC was partly funded by ELAN-Fond of the University Hospital of Erlangen. The BCINIS study is supported in part by the Breast Cancer Research Foundation (BCRF). For BIGGS, ES is supported by NIHR Comprehensive Biomedical Research Centre, Guy’s & St. Thomas’ NHS Foundation Trust in partnership with King’s College London, United Kingdom. IT is supported by the Oxford Biomedical Research Centre. The BReast Oncology Galician Network (BREGAN) is funded by Acción Estratégica de Salud del Instituto de Salud Carlos III FIS PI12/02125/Cofinanciado and FEDER PI17/00918/Cofinanciado FEDER; Acción Estratégica de Salud del Instituto de Salud Carlos III FIS Intrasalud (PI13/01136); Programa Grupos Emergentes, Cancer Genetics Unit, Instituto de Investigacion Biomedica Galicia Sur. Xerencia de Xestion Integrada de Vigo-SERGAS, Instituto de Salud Carlos III, Spain; Grant 10CSA012E, Consellería de Industria Programa Sectorial de Investigación Aplicada, PHEME I + D e I + D Suma del Plan Gallego de Investigación, Desarrollo e Innovación Tecnológica de la Consellería de Industria de la Xunta de Galicia, Spain; Grant EC11-192. Fomento de la Investigación Clínica Independiente, Ministerio de Sanidad, Servicios Sociales e Igualdad, Spain; and Grant FEDER-Interconecta. Ministerio de Economía y Competitividad, Xunta de Galicia, Spain. The BSUCH study was supported by the Dietmar-Hopp Foundation, the Helmholtz Society and the German Cancer Research Center (DKFZ). CCGP is supported by funding from the University of Crete. The CGPS was supported by the Chief Physician Johan Boserup and Lise Boserup Fund, the Danish Medical Research Council, and Herlev and Gentofte Hospital. The CNIO-BCS was supported by the Instituto de Salud Carlos III, the Red Temática de Investigación Cooperativa en Cáncer and grants from the Asociación Española Contra el Cáncer and the Fondo de Investigación Sanitario (PI11/00923 and PI12/00070). COLBCCC is supported by the German Cancer Research Center (DKFZ), Heidelberg, Germany. Diana Torres was in part supported by a postdoctoral fellowship from the Alexander von Humboldt Foundation. The American Cancer Society funds the creation, maintenance, and updating of the CPS-II cohort. The University of Westminster curates the DietCompLyf database funded by Against Breast Cancer Registered Charity No. 1121258 and the NCRN. FHRISK and PROCAS are funded from NIHR grant PGfAR 0707-10031. DGE, AH and WGN are supported by the NIHR Manchester Biomedical Research Centre (IS-BRC-1215-20007). The HABCS study was supported by the Claudia von Schilling Foundation for Breast Cancer Research, by the Lower Saxonian Cancer Society, and by the Rudolf Bartling Foundation. The HEBCS was financially supported by the Helsinki University Hospital Research Fund, the Finnish Cancer Society, and the Sigrid Juselius Foundation. The HERPACC was supported by MEXT Kakenhi (No. 170150181 and 26253041) from the Ministry of Education, Science, Sports, Culture and Technology of Japan, by a Grant-in-Aid for the Third Term Comprehensive 10-Year Strategy for Cancer Control from Ministry Health, Labour and Welfare of Japan, by Health and Labour Sciences Research Grants for Research on Applying Health Technology from Ministry Health, Labour and Welfare of Japan, by National Cancer Center Research and Development Fund, and “Practical Research for Innovative Cancer Control (15ck0106177h0001 and 20ck0106553)” from Japan Agency for Medical Research and development, AMED, and Cancer Bio Bank Aichi. Financial support for KARBAC was provided through the regional agreement on medical training and clinical research (ALF) between Stockholm County Council and Karolinska Institutet, the Swedish Cancer Society, The Gustav V Jubilee foundation and Bert von Kantszows foundation. The KARMA study was supported by Märit.
and Hans Rausings Initiative Against Breast Cancer. iConFab is supported by a grant from the National Breast Cancer Foundation, and previously by the National Health and Medical Research Council (NHMRC), the Queensland Cancer Fund, the Cancer Councils of New South Wales, Victoria, Tasmania and South Australia, and the Cancer Foundation of Western Australia. Financial support for the AOCS was provided by the United States Army Medical Research and Materiel Command [DAMD17-01-1-0729], Cancer Council Victoria, Queenslend Cancer Fund, Cancer Council New South Wales, Cancer Council South Australia, The Cancer Foundation of Western Australia, Cancer Council Tasmania and the National Health and Medical Research Council of Australia (NHMRC; 400413, 400281, 199600). G.C.T. and P.W. are supported by the NHMRC. RB was a Cancer Institute NSW Clinical Research Fellow. The KOHBRA study was partially supported by a grant from the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), and the National R&D Program for Cancer Control, Ministry of Health & Welfare, Republic of Korea (HI16C1127; 1020350; 1420190). LMBC is supported by the 'Stichting tegen Kanker'. DL is supported by the FWO. The MARIE study was supported by the Deutsche Krebshilfe e.V. [70-2892-Br I, 106332, 108253, 108419, 110826, 110828], the Hamburg Cancer Society, the German Cancer Research Center (DKFZ) and the Federal Ministry of Education and Research (BMBF) Germany [01KH0402]. MBCSG is supported by grants from the Italian Association for Cancer Research (AIRC). The MCBCS was supported by the NIH grants R35CA253187, R01CA192393, R01CA116167, R01CA176785 a NIH Specialized Program of Research Excellence (SPORÉ) in Breast Cancer [P50CA116201], and the Breast Cancer Research Foundation. The Melbourne Collaborative Cohort Study (MCCS) cohort recruitment was funded by VicHealth and Cancer Council Victoria. The MCCS was further augmented by Australian National Health and Medical Research Council grants 209057, 396414 and 1074383 and by infrastructure provided by Cancer Council Victoria. Cases and their vital status were ascertained through the Victorian Cancer Registry and the Australian Institute of Health and Welfare, including the National Death Index and the Australian Cancer Database. The MEC was supported by NIH grants CA63464, CA54281, CA098758, CA132839 and CA164973. The MMHS study was supported by NIH grants CA97396, CA128931, CA116201, CA140286 and CA177150. MSKCC is supported by grants from the Breast Cancer Research Foundation and Robert and Kate Niehaus Clinical Cancer Genetics Initiative. The work of MTLGEBCS was supported by the Quebec Breast Cancer Foundation, the Canadian Institutes of Health Research for the “CIHR Team in Familial Risks of Breast Cancer” program – grant # CRN-87521 and the Ministry of Economic Development, Innovation and Export Trade – grant # PSR-SIIRI-701. MYBRCA is funded by research grants from the Wellcome Trust (v203477/2/16/Z), the Malaysian Ministry of Higher Education (UM.C/HIR/MOHE/06) and Cancer Research Malaysia. The NBCS has received funding from the K.G. Jebsen Centre for Breast Cancer Research; the Research Council of Norway grant 193387/V50 (to A-L Børresen-Dale and V.N. Kristensen) and grant 193387/H10 (to A-L Børresen-Dale and V.N. Kristensen), South Eastern Norway Health Authority (grant 39346 to A-L Børresen-Dale) and the Norwegian Cancer Society (to A-L Børresen-Dale and V.N. Kristensen). The Northern California Breast Cancer Family Registry (NC-BCFR) and Ontario Familial Breast Cancer Registry (OFBCR) were supported by grant # PSR SIIRI-701. The ORIGO study was supported by the Dutch Cancer Society (RUL 1997-1505) and the Biobanking and Biomolecular Resources Research Infrastructure (BBMRI-NL CP16). The PBCS was funded by Intramural Research Funds of the National Cancer Institute, Department of Health and Human Services, USA. The POSH study is funded by Cancer Research UK (grants C1275/A11699, C1275/C22524, C1275/A19187, C1275/A15956 and Breast Cancer Campaign 2010PR62, 2013PR044. The RBCS was funded by the Dutch Cancer Society (DDHK 2004-3124, DDHK 2009-4318). The SASBAC study was supported by funding from the Agency for Science, Technology and Research of Singapore (A*STAR), the US
National Institute of Health (NIH) and the Susan G. Komen Breast Cancer Foundation. The SBBCS was supported by Sheffield Experimental Cancer Medicine Centre and Breast Cancer Now Tissue Bank. SEARCH is funded by Cancer Research UK [C490/A10124, C490/A16561] and supported by the UK National Institute for Health Research Biomedical Research Centre at the University of Cambridge. The University of Cambridge has received salary support for PDPP from the NHS in the East of England through the Clinical Academic Reserve. SEBCS was supported by the BRL (Basic Research Laboratory) program through the National Research Foundation of Korea funded by the Ministry of Education, Science and Technology (2012-0000347). SGBCC is funded by the National Research Foundation Singapore, NUS start-up Grant, National University Cancer Institute Singapore (NCIS) Centre Grant, Breast Cancer Prevention Programme, Asian Breast Cancer Research Fund and the NMRC Clinician Scientist Award (SI Category). Population-based controls were from the Multi-Ethnic Cohort (MEC) funded by grants from the Ministry of Health, Singapore, National University of Singapore and National University Health System, Singapore. SKKDKFZS is supported by the DKFZ. The SZBCS was supported by Grant PBZ_KBN_122/P05/2004 and the program of the Minister of Science and Higher Education under the name "Regional Initiative of Excellence" in 2019-2022 project number 002/RID/2018/19 amount of financing 12 000 000 PLN. The TWBCS is supported by the Taiwan Biobank project of the Institute of Biomedical Sciences, Academia Sinica, Taiwan. UBCS was supported by funding from National Cancer Institute (NCI) grant R01 CA163353 (to N.J. Camp) and the Women’s Cancer Center at the Huntsman Cancer Institute (HCI). Data collection for UBCS was supported by the Utah Population Database, Intermountain Healthcare and the Utah Cancer Registry which is funded by the NCI's SEER Program (HHSN261201800016I), the US Centers for Disease Control and Prevention's National Program of Cancer Registries (NU58DP006320), with additional support from the University of Utah and Huntsman Cancer Foundation. The UCIBCS component of this research was supported by the NIH [CA58860, CA92044] and the Lon V Smith Foundation [LVS39420]. The UKBGS is funded by Breast Cancer Now and the Institute of Cancer Research (ICR), London. ICR acknowledges NHS funding to the NIHR Biomedical Research Centre.

Category: Original article
Abstract

**Background:** Predict Breast (www.predict.nhs.uk) is an online prognostication and treatment benefit tool for early invasive breast cancer. The aim of this study was to incorporate the prognostic effect of progesterone receptor (PR) status into a new version of PREDICT and to compare its performance to the current version (2.2).

**Method:** The prognostic effect of PR status was based on the analysis of data from 45,088 European breast cancer patients from 49 studies in the Breast Cancer Association Consortium (BCAC). Cox proportional hazard models were used to estimate the hazard ratio for PR status. Data from a New Zealand study of 11,365 patients with early invasive breast cancer were used for external validation. Model calibration and discrimination were used to test the model performance.

**Results:** Having a PR-positive tumour was associated with a 23% and 28% lower risk of dying from breast cancer for women with ER-negative and ER-positive breast cancer, respectively. The area under the ROC curve (AUC) increased with the addition of PR status from 0.807 to 0.809 for ER-negative patients ($p=0.023$) and from 0.898 to 0.902 for ER-positive patients ($p=2.3\times10^{-6}$) in the New Zealand cohort. Model calibration was modest with 940 observed deaths compared to 1151 predicted.

**Conclusion:** The inclusion of the prognostic effect of PR status to PREDICT Breast has led to an improvement of model performance and more accurate absolute treatment benefit predictions for individual patients. Further studies should determine whether the baseline hazard function requires recalibration.

Abstract word count: 237

*Keywords: prognosis, PREDICT Breast, breast cancer, progesterone receptor*
Introduction

Accurate predictions of individualized survival estimates and benefits of adjuvant therapy following surgery are essential for clinical decision-making for patients with early invasive breast cancer. PREDICT Breast (www.breast.predict.nhs.uk) is an online prognostication and treatment benefit tool to aid clinical decision-making for adjuvant therapy after surgery for patients with early invasive breast cancer [1]. The model uses information about age at diagnosis and tumour characteristics to predict 5-, 10- and 15-year mortality and to predict the benefit of treatment of adjuvant cytotoxic chemotherapy, hormone therapy, trastuzumab and/or bisphosphonate therapy. The clinico-pathological factors used in the current version (v2.2) are tumour size, tumour grade, number of positive lymph nodes, oestrogen receptor (ER) status, human epidermal growth factor receptor 2 (HER2) status, Ki67 status and mode of detection [1]–[3]. PREDICT Breast was developed using cancer registry data from 5,694 women diagnosed in East Anglia, United Kingdom, between 1999 and 2003 [4]. Separate breast cancer specific mortality models were derived for ER-negative tumours and ER-positive tumours. The survival for breast cancer patients is estimated by the hazard ratios of the risk factors in combination with the baseline survival function derived from a Cox proportional hazards regression model. It is possible to include additional prognostic factors into the model, even if data on those factors were not available in the data used to derive the model, by applying external estimates of prognostic effects to the baseline hazard function. This approach was used to incorporate HER2 status and Ki67 status, which led to an improvement in predictive performance [2], [3].

Progesterone receptor (PR) status is a biomarker that has been shown to be prognostic in early invasive breast cancer in a large number of studies [5]–[11]. It is usually assessed by immunohistochemistry (IHC) and, in combination with ER status and HER2 status, can be used to classify the breast carcinoma subtype [7]. Furthermore, the expression levels of PR predict clinical outcomes and the beneficial effect of adjuvant hormonal treatments [6], [8]–[10]. Thus, the addition of PR status to the PREDICT Breast model has the potential to improve the discrimination of the model and improve its clinical utility.

We had two specific aims. The first was to obtain estimates of the relative hazard for breast cancer-specific mortality associated with PR status after adjusting for the prognostic factors included in PREDICT Breast v2.2. The second was to incorporate this hazard ratio estimate into the PREDICT Breast model and compare the performance of the new model against the current model (PREDICT Breast version 2.2).
Methods

Prognostic effect of biomarker PR status

We evaluated the prognostic effect of PR status using data on breast cancer patients of European ancestries collected by 49 studies in the Breast Cancer Association Consortium (BCAC) (Supplementary table S1). All contributing studies were approved by the relevant research ethics committee. Data for women diagnosed with early invasive breast cancer between 1990 and 2017 with complete information on the primary clinico-pathological factors used in the current version of PREDICT v2.2 - tumour size, tumour grade, number of positive lymph nodes, ER status, PR status – were included in the analyses. HER2 status was also available for most patients and could be included as PREDICT allows for missing HER2 data. Mode of detection was missing for 85% of the cases: We assumed that patients aged younger than 50 years or older than 70 years at diagnosis had been clinically detected and mean imputation was used for the remaining missing data. Cases with the following characteristics were excluded: aged younger than 25 or older than 85 at diagnosis, tumour diameter over 20 cm, more than 20 positive lymph nodes. PR status was available for 45,088 patients (13,706 PR-negative tumours and 31,382 PR-positive tumours) (Table 1). Data on ER, HER2 and PR status were collected separately by each study. For some studies the data were from clinical records – and the definition of positivity may have varied from hospital to hospital. Other studies collected pathology material and carried out immunohistochemistry for these markers as part of the research. Different scoring systems and different definitions of positivity were used by different studies. Vital status and cause of death were obtained from the hospital medical records, or the cancer registry or via linkage to death notifications.

We estimated the hazard ratio for PR-positive tumours compared with PR-negative tumours using a Cox proportional hazards model for time to death from breast cancer stratified by study and adjusted for the PREDICT Breast v2.2 prognostic score. The PREDICT Breast v2.2 prognostic score (a log hazard ratio) was calculated for each case according to the formula reported in Candido dos Reis et al (Table 1) [1]. Follow up time was defined as time from diagnosis to last follow-up or death from breast cancer or 15 years after diagnosis, whichever came first. In order to account for prevalent cases time at risk started at study entry (left truncation). This provides an unbiased estimate of the hazard ratio [12]. Separate models were derived for ER-negative breast cancer cases and ER-positive breast cancer cases.

Incorporation of PR status into PREDICT Breast

The absolute risk of breast cancer-specific mortality is estimated in PREDICT Breast by applying the prognostic score to an estimate of the baseline hazard that was developed using a cohort of breast cancer cases with unknown information on PR status. Thus, the underlying baseline hazard represents breast cancer cases with an average PR status. The estimates of the prognostic effects of PR status for ER-negative tumours and ER-positive tumours were therefore rescaled to give an average hazard ratio of unity using a prevalence of PR positivity of 14% in ER-negative cases and 83% in ER-positive tumours.

Validation study population

Data from a New Zealand population-based cancer registry were used for model validation [13]. Data were available on 11,365 early invasive breast cancer patients (2,194 ER-negative and 9,171 ER-positive) diagnosed between 2000 and 2014 after exclusion of cases with metastasis at diagnosis (639), those younger than 25 or older than 85 years old (524), tumour diameter larger than 20 cm (5), more than 20 positive lymph nodes (232), inconsistent follow up time information (2) and those that did not undergo primary surgery (938).

Information on adjuvant systemic cancer treatments, chemotherapy and hormone therapy, were also recorded. The New Zealand cohort did not include information on specific chemotherapy regimes. To derive the prognostic score we assumed that patients who underwent chemotherapy before 2010 were treated with anthracycline-based regimen and for those treated after this time we assumed a taxane-based regimen.
This is based on data for the most commonly used regimen in New Zealand (Mark Elwood personal communication). In addition, information on the use of trastuzumab was not collected during follow up. We assume that patients with a positive HER2 tumour and that were diagnosed after 2010, underwent trastuzumab treatment.

Dates and causes of death were extracted from the hospital records and from mortality records until 31 December 2014 and all patients were censored after this date. The primary endpoint was breast cancer-specific survival. The expected survival probability for each patient was based on a follow-up time that was different for each patient up to a maximum of 15 years. For patients that survived, follow-up was from date of diagnosis until date of last follow up. For patients that died potential follow up time was calculated as if the patient had survived to the end of the study, that is from date of diagnosis until 31st December 2014.

For each patient, their breast cancer risk predictions were estimated using the two models; PREDICT version 2.2 and PREDICT version 2.2 with the inclusion of PR status (v2.3). Model calibration was performed to investigate the accuracy of the mortality estimates predicted by each model compared to the observed mortality rate. Additionally, a Chi-square test was used as a goodness-of-fit test in which the observed events were also compared with the number of predicted events (1 d.f.). Model discrimination was also evaluated through the calculation of the AUC (area under the receiver-operator-characteristic curve) for up to 15-year breast cancer mortality. The AUC was used to measure the accuracy of classification of cases and non-cases for the two prediction models and to test for any beneficial effect of the addition of PR status to PREDICT Breast. Comparison of AUCs was done using the method of De Long et al (1988) [14] implemented in the R package pROC. All analyses were conducted using R v4.1.2 in the R Studio environment.
Results

The 49 BCAC studies included 45,088 eligible European patients of whom 13,706 (30%) had PR-negative tumours and 31,382 (70%) had PR positive tumours (Table 1). During follow-up there were 6,974 recorded deaths with approximately 11 breast cancer deaths per 1,000 person-years. The patient characteristics of the New Zealand cohort were very similar to those in the studies of BCAC apart from the proportion of patients that underwent chemotherapy (35%), which was lower than that for BCAC (46%).

Table 1. Patient characteristics for the BCAC studies with European breast cancer patients ($n = 45,088$) and the New Zealand validation cohort ($n = 11,365$)

|                          | BCAC European ancestries | New Zealand cohort |
|--------------------------|--------------------------|--------------------|
| Age, years               | N = 45088                | N = 11365          |
|                          | Mean (sd), Unless stated otherwise | Mean (sd), Unless stated otherwise |
| Follow-up time, years    | 57.1 (11.9)              | 57.1 (12.2)        |
| Tumour size, cm          | 2.1 (1.5)                | 2.3 (1.7)          |
| Tumour grade, n (%)      |                          |                    |
| Grade 1                  | 8776 (19.5)              | 2841 (25.0)        |
| Grade 2                  | 21945 (48.7)             | 5312 (46.7)        |
| Grade 3                  | 14367 (31.9)             | 3212 (28.3)        |
| ER/PR status, n(%)       |                          |                    |
| ER-/PR-                  | 7474 (16.6)              | 2026 (17.8)        |
| ER-/PR+                  | 1187 (2.6)               | 168 (1.5)          |
| ER+/PR-                  | 6232 (13.8)              | 1583 (13.9)        |
| ER+/PR+                  | 30195 (67.0)             | 7588 (66.8)        |
| HER2 status, n (%)       |                          |                    |
| Negative                 | 27108 (83.9)             | 7774 (84.4)        |
| Positive                 | 5220 (16.1)              | 1439 (15.6)        |
| No. of positive lymph nodes | 1.2 (2.7)             | 1.7 (3.4)          |
| Mode of detection, n (%) |                          |                    |
| Clinically detected      | 21639 (48.0)             | 6516 (57.3)        |
| Screen detected          | 2433 (5.4)               | 4849 (42.7)        |
| Missing                  | 21016 (46.6)             |                    |
| Chemotherapy, n (%)      | N = 36991                | N = 11365          |
| No                       | 20157 (54.5)             | 7391 (65.0)        |
| Yes                      | 16834 (45.5)             | 3974 (35.0)        |
| Hormone therapy, n (%)   | N = 35486                | N = 11365          |
| No                       | 10724 (30.2)             | 4340 (38.2)        |
| Yes                      | 24762 (69.8)             | 7025 (61.8)        |
| Radiotherapy, n(%)       | N = 32166                |                    |
| No                       | 8360 (26.0)              |                    |
| Yes                      | 23806 (74.0)             |                    |
| Trastuzumab, n(%)        | N = 22529                |                    |
| No                       | 20997 (93.2)             |                    |
| Yes                      | 1532 (6.8)               |                    |
| Number of deaths, n(%)   | N = 45081                | N = 11365          |
| Breast cancer            | 3531 (59.6)              | 940 (58.2)         |
| Other causes             | 2394 (40.4)              | 568 (35.3)         |
| Unknown causes           | 101 (6.3)                |                    |

Initial analyses were restricted to patients of European ancestries. In univariate analyses, PR expression was associated with a better prognosis, with the magnitude of the effect being greater in ER-positive disease (Table 2). The effect of PR expression was attenuated after adjusting for other prognostic factors. We evaluated whether the effect of PR varied by age or HER2 status by including an interaction term in the multi-
variable model. There was little evidence for interaction for either age at diagnosis ($p = 0.65$ in ER positive and $p = 0.43$ in ER negative) or HER2 status ($p = 0.36$ in ER positive and $p = 0.91$ in ER negative).

We also assessed between-study heterogeneity and plotted the estimated beta coefficient of PR status per study adjusted for the prognostic index (Supplementary Fig. S1). There was no evidence of heterogeneity in the ER-negative model ($p = 0.99$) or in the ER-positive model ($p = 0.26$).

Visual examination of plots of log-cumulative hazard against log-time and of the Schoenfeld residuals against time showed that there was no serious violation of the proportional hazards assumption (Supplementary Fig. S2 and Fig. S3). The hazard ratios for the other prognostic factors from the multivariable model that included each prognostic factor separately were slightly different to those in the PREDICT model. Of particular note is that in the BCAC dataset a significant association was observed for mode of detection in ER-negative disease. It has previously been reported to be associated only in ER-positive tumours.

Table 2. Hazard ratios (95% C.I.) for progesterone receptor (PR) status and other prognostic factors for breast cancer specific mortality stratified by oestrogen receptor (ER) status and study derived from the BCAC data for European ancestries.

|                          | ER negative       | p-value | ER positive       | p-value |
|--------------------------|-------------------|---------|-------------------|---------|
| **Univariable**          |                   |         |                   |         |
| PR+ v PR-                | 0.65 (0.54 - 0.80) | 2.0 x 10^{-5} | 0.60 (0.55 - 0.67) | < 10^{-15} |
| **Multivariable with PREDICT prognostic index** |                   |         |                   |         |
| PR+ v PR-                | 0.77 (0.64 – 0.94) | 0.009 | 0.72 (0.65 – 0.79) | 3.7x10^{-11} |
| **Multivariable with individual prognostic factors** |                   |         |                   |         |
| PR+ v PR-                | 0.76 (0.60 – 0.98) | 0.031 | 0.69 (0.62 – 0.78) | 1.6x10^{-9} |
| Age diagnosis (per 5 years) | 1.04 (1.00 – 1.08) | 0.028 | 1.03 (1.00 – 1.06) | 0.030 |
| Size (per cm)            | 1.17 (1.13 – 1.22) | < 10^{-15} | 1.13 (1.10 – 1.16) | < 10^{-15} |
| Nodes (per positive node) | 1.13 (1.11 – 1.14) | < 10^{-15} | 1.12 (1.10 – 1.13) | < 10^{-15} |
| Grade                    |                   |         |                   |         |
| 2 v 1                    | 2.22 (1.20 – 4.10) | 0.011 | 2.51 (2.04 – 3.08) | < 10^{-15} |
| 3 v 1                    | 2.52 (1.38 – 4.62) | 2.7x10^{-3} | 4.26 (3.44 – 5.28) | < 10^{-15} |
| Screen detected v clinically detected | 0.65 (0.45 – 0.93) | 0.018 | 0.53 (0.43 – 0.65) | 1.1x10^{-9} |
| HER2+ v HER2-            | 0.96 (0.81 – 1.13) | 0.603 | 1.10 (0.96 – 1.26) | 0.163 |

*PRS coefficient constraint to be one

In order to apply the PR hazard ratio to the PREDICT Breast baseline hazard it needed to be rescaled such that the mean hazard ratio was unity with the purpose that the reference category for the hazard ratio is a hypothetical case with average PR status. The proportion of cases that are PR positive used for rescaling was the average from the combined BCAC studies (14% for ER negative and 83% for ER positive cases). The rescaled hazard ratios were 1.03 for PR negative/ER negative, 0.80 for PR positive/ER negative, 1.30 for PR negative/ER positive and 0.94 for PR positive/ER positive. The hazard ratios for all the other prognostic variables and the baseline hazard function remained unchanged from PREDICT Breast v2.2.
The performance of PREDICT Breast v2.2 with the addition of PR status was then evaluated in the independent New Zealand data set and compared with v2.2. The discrimination for up to 15-year breast cancer-specific mortality of PREDICT as measured by the AUC increased from 0.807 to 0.809 ($p = 0.023$) for ER-negative patients and from 0.898 to 0.902 ($p = 2.3 \times 10^{-6}$) for ER-positive cases (Table 3). The calibration of the model was modest, with 1151 breast cancer deaths predicted compared to 940 that were observed during a 15-year follow up (goodness-of-fit chi-squared test $p = 5.0 \times 10^{-10}$) (Table 4). Overestimation was worse ER-negative European (366 predicted compared with 281 observed, $p = 8.9 \times 10^{-6}$) than ER-positive European patients (442 predicted compared to 414 observed, $p = 0.183$). Across ethnicities, the model performs better in ER-positive cases in comparison to ER-negative cases. Figure 1 shows the calibration of PREDICT Breast including PR status across quintiles of predicted risk.

The number of observed and predicted deaths from other causes and deaths from all causes in the New Zealand cohort are shown in Table 5 and Table 6. Overall, PREDICT Breast with the inclusion of PR status shows to be well-calibrated in predicting non-breast cancer specific mortality with an over-estimation of 0.4% (670 predicted compared with 667 observed, $p = 0.908$). The model shows to be slightly over-estimating the number of non-breast cancer deaths in patients of European descent by 6.8% (546 predicted compared with 511 observed, $p = 0.134$), whilst in patients from Pacific origin they are slightly under-estimated (28 predicted compared with 32 observed, $p = 0.450$). While the model performs better in these ethnic groups, it performs worse in Māori patients (40 predicted compared with 88 observed, $p = 3.2 \times 10^{-14}$). Both models (PREDICT Breast vs PREDICT Breast including PR status) show to over-estimate the all-cause mortality by approximately 13%, regardless of ER status. Similar to the other-cause mortality results, the models show to over-estimate the number of predicted all-cause deaths in most ethnic groups. However, there is an under-estimation of all-cause deaths in patients of Māori descent.

Table 3. The discrimination for up to 15-year breast cancer-specific mortality in the New Zealand validation cohort

|              | C-index without PR status | C-index with PR status | p-value   |
|--------------|---------------------------|-----------------------|-----------|
| **ER specific** |                           |                       |           |
| ER-negative  | 0.807                     | 0.809                 | 0.023     |
| ER-positive  | 0.898                     | 0.902                 | 2.3 \times 10^{-6} |
| **Ethnicity** |                           |                       |           |
| Māori        | 0.901                     | 0.901                 | 0.983     |
| Pacific      | 0.897                     | 0.898                 | 0.883     |
| European     | 0.878                     | 0.881                 | 1.0 \times 10^{-6} |
| Other ethnicity | 0.919                 | 0.923                 | 0.022     |
| Overall      | 0.885                     | 0.888                 | 1.5 \times 10^{-7} |
**Table 4.** Cumulative observed vs predicted breast cancer deaths at up to 15 years follow up by ethnicity in the New Zealand cohort

| Number of deaths | Total number of breast cancer patients by ethnic group | Predicted breast cancer specific mortality | Observed breast cancer specific mortality |
|------------------|--------------------------------------------------|------------------------------------------|------------------------------------------|
|                  |                                                  | Without PR status | With PR status                           |
| **Without PR status** |                                                  |                  |                                          |
| Māori            | 1054                                             | 117             | 117                                      | 108                                      |
| Pacific          | 666                                              | 90              | 90                                       | 70                                       |
| European         | 8220                                             | 799             | 808                                      | 695                                      |
| Other            | 1257                                             | 121             | 122                                      | 66                                       |
| Missing          | 168                                              | 14              | 14                                       | 1                                        |
| **Total**        | 11365                                            | 1141            | 1151                                     | 940                                      |
| **With PR status** |                                                  |                  |                                          |
| Māori            | 177                                              | 52              | 52                                       | 44                                       |
| Pacific          | 153                                              | 43              | 44                                       | 31                                       |
| European         | 1576                                             | 363             | 366                                      | 281                                      |
| Other            | 258                                              | 58              | 58                                       | 35                                       |
| Missing          | 30                                               | 7               | 8                                        | 1                                        |
| **Total**        | 2194                                             | 523             | 528                                      | 392                                      |

**ER specific**

**ER-**

| Māori            | 177                                              | 52              | 52                                       | 44                                       |
| Pacific          | 153                                              | 43              | 44                                       | 31                                       |
| European         | 1576                                             | 363             | 366                                      | 281                                      |
| Other            | 258                                              | 58              | 58                                       | 35                                       |
| Missing          | 30                                               | 7               | 8                                        | 1                                        |
| **Total**        | 2194                                             | 523             | 528                                      | 392                                      |

**ER+**

| Māori            | 877                                              | 65              | 65                                       | 64                                       |
| Pacific          | 513                                              | 47              | 46                                       | 39                                       |
| European         | 6644                                             | 436             | 442                                      | 414                                      |
| Other            | 999                                              | 63              | 64                                       | 31                                       |
| Missing          | 138                                              | 6               | 6                                        | 0                                        |
| **Total**        | 9171                                             | 617             | 623                                      | 548                                      |
Table 5. Cumulative observed vs predicted other-cause/non-breast cancer deaths at up to 15 years follow up by ethnicity in the New Zealand cohort

| Number of deaths | Total number of breast cancer patients by ethnic group | Other-cause/Non-breast cancer specific mortality | Observed other-cause mortality |
|------------------|-----------------------------------------------------|-----------------------------------------------|--------------------------------|
|                  |                                                     | Without PR status | With PR status                              |                                |
| Māori            | 1054                                                | 40               | 40                                           | 88                             |
| Pacific          | 666                                                 | 27               | 28                                           | 32                             |
| European         | 8220                                                | 547              | 546                                          | 511                            |
| Other            | 1257                                                | 47               | 47                                           | 36                             |
| Missing          | 168                                                 | 9                | 9                                            | 0                              |
| Total            | 11365                                               | 671              | 670                                          | 667                            |
| ER specific      |                                                     |                  |                                              |                                |
| ER-              |                                                     |                  |                                              |                                |
| Māori            | 177                                                 | 7                | 7                                            | 16                             |
| Pacific          | 153                                                 | 6                | 6                                            | 6                              |
| European         | 1576                                                | 101              | 101                                          | 100                            |
| Other            | 258                                                 | 9                | 9                                            | 8                              |
| Missing          | 30                                                  | 2                | 2                                            | 0                              |
| Total            | 2194                                                | 125              | 125                                          | 130                            |
| ER+              |                                                     |                  |                                              |                                |
| Māori            | 877                                                 | 34               | 34                                           | 72                             |
| Pacific          | 513                                                 | 21               | 21                                           | 26                             |
| European         | 6644                                                | 446              | 446                                          | 411                            |
| Other            | 999                                                 | 38               | 38                                           | 28                             |
| Missing          | 138                                                 | 7                | 7                                            | 0                              |
| Total            | 9171                                                | 546              | 546                                          | 537                            |
Table 6. Cumulative observed vs predicted all-cause deaths at up to 15 years follow up by ethnicity in the New Zealand cohort

| Number of deaths | Total number of breast cancer patients by ethnic group | All-cause mortality | Observed all-cause mortality |
|------------------|-------------------------------------------------------|---------------------|-----------------------------|
|                  |                                                       | Without PR status   | With PR status              |
| Māori            | 1054                                                  | 157                | 157                         | 196                         |
| Pacific          | 666                                                   | 118                | 118                         | 102                         |
| European         | 8220                                                  | 1346               | 1355                        | 1206                        |
| Other            | 1257                                                  | 168                | 169                         | 102                         |
| Missing          | 168                                                   | 23                 | 23                          | 1                           |
| Total            | 11365                                                 | 1811               | 1821                        | 1607                        |

| ER specific |                                                       | Without PR status   | With PR status              |
|-------------|-------------------------------------------------------|---------------------|-----------------------------|
| ER-         |                                                       |                     |                             |
| Māori       | 177                                                   | 59                  | 59                          | 60                          |
| Pacific     | 153                                                   | 50                  | 50                          | 37                          |
| European    | 1576                                                  | 464                 | 467                         | 381                         |
| Other       | 258                                                   | 67                  | 67                          | 43                          |
| Missing     | 30                                                    | 9                   | 9                           | 1                           |
| Total       | 2194                                                  | 648                 | 652                         | 522                         |

| ER+         |                                                       |                     |                             |
|-------------|-------------------------------------------------------|---------------------|-----------------------------|
| Māori       | 877                                                   | 98                  | 98                          | 136                         |
| Pacific     | 513                                                   | 68                  | 67                          | 65                          |
| European    | 6644                                                  | 882                 | 888                         | 825                         |
| Other       | 999                                                   | 101                 | 102                         | 59                          |
| Missing     | 138                                                   | 14                  | 13                          | 0                           |
| Total       | 9171                                                  | 1163                | 1169                        | 1085                        |
We then carried out a sensitivity analysis using alternative assumptions for chemotherapy and trastuzumab treatment. Table S2 shows the predicted breast cancer deaths with the assumption that patients who underwent chemotherapy were treated with anthracycline-based regimen (second-generation regimen). Table S3 shows the predicted breast cancer deaths with the assumptions that all patients with HER2 positive tumours were treated with trastuzumab, and patients that underwent chemotherapy and were diagnosed before 2010 were treated with anthracycline-based regimen and for those diagnosed after this time were treated with a taxane-based regimen. The model appears to be mis-calibrated and results show that the calibration is sensitive to the treatment assumptions made prior to the analyses.

In order to determine the clinical impact of the small improvement in discrimination we estimated the reclassification of risk for PREDICT v2.2 + PR compared to PREDICT v 2.2 based on classifying cases from the New Zealand cohort into three categories of breast cancer specific mortality at ten years; less than 15%, 15% to less than 20% and 20% or greater. These thresholds are approximately equivalent to the thresholds for absolute risk reduction of chemotherapy of 3% and 5% used by the Cambridge Breast Unit Multidisciplinary Team for clinical decision making [15]. Table 7 shows that in total 4.2% of cases changed risk category, of which 2.4% changed from a lower risk category to a higher risk category.

**Figure 1.** Calibration plot of observed outcomes at 15 years after diagnosis with 95% confidence intervals against 15-year predicted outcomes at by quintiles of the predicted value in the New Zealand cohort.
**Table 7.** Reclassification of predicted breast cancer specific mortality following the inclusion of PR status into PREDICT Breast

| Predicted breast cancer specific mortality | PREDICT Breast (including PR status) | [0.00 – 0.15) | [0.15 – 0.20) | [0.20 – 1.00] |
|------------------------------------------|--------------------------------------|----------------|----------------|----------------|
| [0.00 – 0.15)                            | 7191 (63.3%)                         | 137 (1.2%)     | 0 (0%)         |                |
| [0.15 – 0.20)                            | 115 (1.0%)                           | 859 (7.6%)     | 138 (1.2%)     |                |
| [0.20 – 1.00]                            | 0 (0%)                               | 92 (0.8%)      | 2833 (24.9%)   |                |
Discussion

The primary aim of this study was to estimate the prognostic effect – as the relative hazard - of progesterone receptor expression in breast cancer after adjusting for the other prognostic factors incorporated in the PREDICT Breast prognostic tool. Importantly, the effects of other prognostic factors were constrained to the same effect sizes as used in the PREDICT Breast model. This enabled us to incorporate progesterone expression into PREDICT Breast by applying the relative hazard to the baseline hazard which is specified in the PREDICT Breast model. The Breast Cancer Association Consortium data set on which this analysis was based is large, with over 45,000 cases of European ancestries from 49 separate studies from around the world and over 3,500 deaths from breast cancer during follow-up. In addition to the large sample size, the heterogeneity inherent in combining data from multiple studies is a strength as the findings should be robust and widely generalisable. While a large number of cases of south Asian ancestries were also available from the BCAC data set there was a small number of breast cancer deaths during follow-up and the impact of ancestry on the association between progesterone receptor expression and prognosis could not be reliably assessed.

The heterogeneity of study design and conduct is also reflected in the measurement of the prognostic factors included in the analyses. In particular, different studies used different data sources to determine ER, HER2 and PR status including clinical records and research data. Consequently, different studies used slightly different definitions to classify ER, HER2 and PR status and these data could not be fully harmonised across studies. Any measurement error resulting from this is likely to have biased the association of PR status with survival towards the null but any such bias is expected to be small.

Our results are broadly similar to the extensive published data [5]–[11], [16], [17] and show that patients with a positive PR tumour have a better survival than patients with a PR-negative tumour regardless of their ER status. There was little difference in the relative hazard estimates after adjusting for a prognostic index constrained to the effect size used in the PREDICT Breast model or in full, multi-variable model that allowed the hazard ratios for the other prognostic factors to fit the data. Previous reports have shown that the prognostic effect of PR status varies with age at diagnosis with a bigger effect being observed in younger patients [16], [17], particularly during the first five years of follow in one of the studies [16]. However, we found little evidence for a difference in the effect with age.

We used the relative hazard estimates to incorporate progesterone receptor expression into the PREDICT Breast model and compared the performance of the modified model with that of the current version of PREDICT Breast as used in the online web tool (v2.2). This was done using a completely independent data set from New Zealand. The addition of a single prognostic factor to a multi-variable prediction model would not be expected to improve the performance of the model substantially. Nevertheless, the addition of PR status resulted in a small, but statistically significant improvement in the discrimination of PREDICT Breast compared with the current version. Similarly, the small proportion of patients being reclassified when using clinically relevant categories of risk that was observed was as would be expected. The calibration of the modified version of PREDICT Breast would not be expected to change much as calibration is primarily dependent on the baseline hazard which was the same in the modified and current models and then depends on the assumption about the proportion of cases that are PR positive used to rescale the hazard ratios as described in the methods. The calibration of the modified models in an independent data set was modest with the number of breast cancer deaths in the New Zealand cohort being overestimated by 22%. This was, as expected, similar – albeit slightly worse - to the calibration of the current model. The mis-calibration was similar for all ancestries and was worse in ER negative patients. PREDICT Breast has previously been shown to be well-calibrated in cases series from the UK, Canada, the Netherlands and Malaysia and the reasons for the poorer performance in the New Zealand data set are not clear. One possible explanation is that the baseline hazard for PREDICT is based on a cohort of patients from the UK diagnosed from 1999-2004 whereas the New Zealand cohort was diagnosed from 2000-2014. There have been improvements in prognosis over
time and so some overestimation of deaths is expected. This is supported by the observation that there is an improvement in the calibration of PREDICT Breast including PR status when performing analysis on patients diagnosed between 2000 and 2004, with an over-estimation in breast cancer deaths of 7.7% in all patients and 3.6% in European patients, compared to 22.4% and 16.3% for patients diagnosed between 2000 and 2014. Some of these improvements are the result of the introduction of newer therapies such as bisphosphonates, increased duration of hormone therapies and improvements in the management of disease at the time of relapse. However, information on these therapies was not available for the validation data and so could not be accounted for in the analyses. A simple country-specific recalibration of the baseline hazard function or a re-estimation of the baseline hazard using more contemporaneous data would improve the model performance.

The expression of biomarkers such as ER, HER2 and PR is continuous but then dichotomised based on a threshold for use in clinical practice. For ER and HER2 status this is primarily done to facilitate decision making for specific adjuvant therapies. There is good evidence that the prognostic effect of these biomarkers varies with the level of expression [18]–[20] and the inclusion of a multi-category ordinal scale or a continuous measure of expression in the model has the potential to improve model performance.

In conclusion, the incorporation of the prognostic effect of PR status into PREDICT Breast has resulted in a small, statistically significant improvement in discrimination with some reclassification in clinically relevant risk thresholds. On the other hand, the calibration of the modified PREDICT model in an independent data set was slightly poorer. The improvement in discrimination is likely to be generalisable across diverse case cohorts as it is primarily dependent on the magnitude of the hazard ratio associated with progesterone receptor status which is likely to be robustly estimated. In contrast, calibration is dependent on the baseline hazard which may vary across different populations and time periods as well as the distribution of the biomarker in different populations. Thus, progesterone receptor expression will be included into a new version of PREDICT Breast (v2.3) based on the improvement in discrimination and the reclassification. Further studies should investigate the potential improvement that recalibrating the baseline hazard function could have on country-specific model performance.
Acknowledgements

We thank all the individuals who took part in these studies and all the researchers, clinicians, technicians and administrative staff who have enabled this work to be carried out. ABCS thanks the Blood bank Sanquin, The Netherlands. ABCTB Investigators: Christine Clarke, Deborah Marsh, Rodney Scott, Robert Baxter, Desmond Yip, Jane Carpenter, Alison Davis, Nirmala Pathmanathan, Peter Simpson, John Dy, Graham, Mythily Sachchithananthan. Samples are made available to researchers on a non-exclusive basis. The BCINIS study would not have been possible without the contributions of Dr. K. Landsman, Dr. N. Gronich, Dr. A. Flugelman, Dr. W. Saliba, Dr. F. Lejkowicz, Dr. E. Liani, Dr. I. Cohen, Dr. S. Kalet, Dr. D. Friedman, Dr. O. Barnet of the NICCC in Haifa, and all the contributing family medicine, surgery, pathology and oncology teams in all medical institutes in Northern Israel. BIGGS thanks Niall McInerney, Gabrielle Colleran, Andrew Rowan, Angela Jones. The BREOGAN study would not have been possible without the contributions of the following: Manuela Gago-Dominguez, Jose Esteban Castelao, Angel Carracedo, Victor Muñoz Garzón, Alejandro Novo Domínguez, Maria Elena Martínez, Sara Miranda Ponte, Carmen Redondo Marey, Maite Peña Fernández, Manuel Enguíx Castelo, Maria Torres, Manuel Calaza (BREOGAN), José Antúnez, Máximo Fraga and the staff of the Department of Pathology and Biobank of the University Hospital Complex of Santiago-CHUS, Instituto de Investigación Sanitaria de Santiago, IDIS, Xerencia de Xestion Integrada de Santiago-SERGAS; Joaquín González-Carreró and the staff of the Department of Pathology and Biobank of University Hospital Complex of Vigo, Instituto de Investigación Biomedica Galicia Sur, SERGAS, Vigo, Spain. The BSUCH study acknowledges the Principal Investigator, Barbara Burwinkel, and, thanks Peter Bugert, Medical Faculty Mannheim. CCGP thanks Styliani Apostolaki, Anna Margioli, Georgios Nitos, Maria Perraki, Georgia Saloustrou, Georgia Sevastaki, Konstantinos Pompodakis. CGPS thanks staff and participants of the Copenhagen General Population Study. For the excellent technical assistance: Dorthe Uldall Andersen, Maria Birna Arnadottir, Anne Bank, Dorthe Kjeldgård Hansen. The Danish Cancer Biobank is acknowledged for providing infrastructure for the collection of blood samples for the cases. CNIO-BCS thanks Guillermo Pita, Charo Alonso, Nuria Álvarez, Pilar Zamora, Primitiva Menendez, the Human Genotyping-CEGEN Unit (CNIO). COLBCCC thanks all patients, the physicians Justo G. Olaya, Mauricio Tawil, Lilian Torregrosa, Elias Quintero, Sebastian Quintero, Claudia Ramírez, José J. Caicedo, and Jose F. Robledo, and the technician Michael Gilbert for their contributions and commitment to this study. Investigators from the CPS-II cohort thank the participants and Study Management Group for their invaluable contributions to this research. They also acknowledge the contribution to this study from central cancer registries supported through the Centers for Disease Control and Prevention National Program of Cancer Registries, as well as cancer registries supported by the National Cancer Institute Surveillance Epidemiology and End Results program. DIETCOMPLYF thanks the patients, nurses and clinical staff involved in the study. The DietCompLyf study was funded by the charity Against Breast Cancer (Registered Charity Number 1121258) and the NCRN. FHRISK and PROCAS thank NIHR for funding. HEBCS thanks Johanna Kiiski, Carl Blomqvist, Taru A. Muranen, Kristiina Aittonmäki, Kirsimari Aaltonen, Karl von Smitten, Irja Erkkilä. HKBCS thanks Hong Kong Sanatorium and Hospital, Dr Ellen Li Charitable Foundation, The Kerry Group Kuok Foundation, National Institute of Health 1R03CA130065 and the North California Cancer Center for support. KARMA and SASBAC thank the Swedish Medical Research Counsel. kConFab/AOCS wish to thank Heather Thorne, Eveline Niedermayr, all the KConFab research nurses and staff, the heads and staff of the Family Cancer Clinics, and the Clinical Follow Up Study (which has received funding from the NHMRC, the National Breast Cancer Foundation, Cancer Australia, and the National Institute of Health (USA)) for their contributions to this resource, and the many families who contribute to kConFab. We thank all investigators of the KOHGRA (Korean Hereditary Breast Cancer) Study. LMBC thanks Gilian Peuteman, Thomas Van Brussel, Evy Vanderheyden and Kathleen Corthouts. MARIE thanks Petra Seibold, Nadia Obi, Sabine Behrens, Ursula Eilber and Muhabet Celik. MBCSG (Milan Breast Cancer Study Group): Paolo Radice, Paolo Peterlongo, Siranoush Manoukian, Bernard Peissel, Jacopo Azzollini, Erica Rosina, Daniela Zaffaroni, Bernardo Bonanni, Irene Feroce, Mariarosaria Calvello, Aliana Guerrieri Gonzaga, Monica Marabelli, Davide Bondavalli and the personnel of the Cogentech Cancer Genetic Test Laboratory. The MCCS was made possible by the contribution of many people, including the original
investigators, the teams that recruited the participants and continue working on follow-up, and the many thousands of Melbourne residents who continue to participate in the study. We thank the coordinators, the research staff and especially the MMHS participants for their continued collaboration on research studies in breast cancer. MSKCC thanks Marina Corines, Lauren Jacobs. MYBRCA thanks study participants and research staff (particularly Patsy Ng, Nurhidayu Hassan, Yoon Sook-Yee, Daphne Lee, Lee Sheau Yee, Phuah Sze Yee and Norhashimah Hassan) for their contributions and commitment to this study. The following are NBCS Collaborators: Kristine K. Sahlberg (PhD), Anne-Lise Børresen-Dale (Prof. Em.), Lars Ottestad (MD), Rolf Kåresen (Prof. Em.) Dr. Ellen Schlichting (MD), Marit Muri Holmen (MD), Toril Sauer (MD), Vilde Haakenson (MD), Olav Engebretsen (MD), Bjørn Naume (MD), Alexander Fosså (MD), Cecile E. Kiserud (MD), Kristin V. Reinertsen (MD), Åslaug Helland (MD), Margit Riis (MD), Jürgen Geisler (MD), OSBREAC and Grethe I. Grenaker Alnæs (MSc). OBCS thanks Arja Jukkola-Vuorinen, Mervi Grip, Saila Kauppila, Meeri Otsukka, Leena Keskitalo and Kari Mononen for their contributions to this study. The OFBCR thanks Teresa Selander, Nayana Weerasooriya and Steve Gallinger. ORIGO thanks E. Krol-Warmerdam, and J. Blom for patient accrual, administering questionnaires, and managing clinical information. The LUMC survival data were retrieved from the Leiden hospital-based cancer registry system (ONCDOC) with the help of Dr. J. Molenaar. PBCS thanks Louise Brinton, Mark Sherman, Neonila Szeszenia-Dabrowska, Beata Peplonska, Witold Zatonski, Pei Chao, Michael Stagner. The ethical approval for the POSH study is MREC /00/6/69, UKCRN ID: 1137. We thank staff in the Experimental Cancer Medicine Centre (ECMC) supported Faculty of Medicine Tissue Bank and the Faculty of Medicine DNA Banking resource. The authors wish to acknowledge the roles of the Breast Cancer Now Tissue Bank in collecting and making available the samples and/or data, and the patients who have generously donated their tissues and shared their data to be used in the generation of this publication. PREFACE thanks Sonja Oeser and Silke Landrith. The RBCS thanks Jannet Blom, Saskia Pelders, Wendy J.C. Prager – van der Smissen, and the Erasmus MC Family Cancer Clinic. SBCS thanks Sue Higham, Helen Cramp, Dan Connelly, Ian Brock, Sabapathy Balasuhramanian and Malcolm W.R. Reed. We thank the SEARCH and EPIC teams. SGBCC thanks the participants and all research coordinators for their excellent help with recruitment, data and sample collection. SKKDKFS thanks all study participants, clinicians, family doctors, researchers and technicians for their contributions and commitment to this study. We thank the SUCCESS Study teams in Munich, Duesseldorf, Erlangen and Ulm. SZBCS thanks Ewa Putresza. UBCS thanks all study participants, the ascertainment, laboratory and research informatics teams at Huntsman Cancer Institute and Intermountain Healthcare, and Justin Williams, Brandt Jones, Myke Madsen, Stacey Knight and Kerry Rowe for their important contributions to this study. UCIBCS thanks Irene Masunaka. UKBGS thanks Breast Cancer Now and the Institute of Cancer Research for support and funding of the Generations Study, and the study participants, study staff, and the doctors, nurses and other health care providers and health information sources who have contributed to the study. We acknowledge NHS funding to the Royal Marsden/ICR NIHR Biomedical Research Centre.

This work was supported by The Mark Foundation for Cancer Research and the Cancer Research UK Cambridge Centre [C9685/A25177].

Declaration of Interest statement

None declared.
Bibliography

[1] F. J. Candido dos Reis et al., “An updated PREDICT breast cancer prognostication and treatment benefit prediction model with independent validation,” Breast Cancer Research, 2017, doi: 10.1186/s13058-017-0852-3.

[2] G. C. Wishart et al., “PREDICT Plus: Development and validation of a prognostic model for early breast cancer that includes HER2,” British Journal of Cancer, 2012, doi: 10.1038/bjc.2012.338.

[3] G. C. Wishart et al., “Inclusion of Ki67 significantly improves performance of the PREDICT prognostication and prediction model for early breast cancer,” BMC Cancer, 2014, doi: 10.1186/1471-2407-14-908.

[4] G. C. Wishart et al., “PREDICT: A new UK prognostic model that predicts survival following surgery for invasive breast cancer,” Breast Cancer Research, 2010, doi: 10.1186/bcr2464.

[5] F. M. Blows et al., “Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: A collaborative analysis of data for 10,159 cases from 12 studies,” PLoS Medicine, 2010, doi: 10.1371/journal.pmed.1000279.

[6] C. A. Purdie et al., “Progesterone receptor expression is an independent prognostic variable in early breast cancer: A population-based study,” British Journal of Cancer, 2014, doi: 10.1038/bjc.2013.756.

[7] X. Dai, L. Xiang, T. Li, and Z. Bai, “Cancer hallmarks, biomarkers and breast cancer molecular subtypes,” J Cancer, 2016, doi: 10.7150/jca.13141.

[8] V. J. Bardou, G. Arpino, R. M. Elledge, C. K. Osborne, and G. M. Clark, “Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases,” Journal of Clinical Oncology, 2003, doi: 10.1200/JCO.2003.09.099.

[9] X. Cui, R. Schiff, G. Arpino, C. K. Osborne, and A. v. Lee, “Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy,” Journal of Clinical Oncology, 2005. doi: 10.1200/JCO.2005.09.004.

[10] M. Dowsett et al., “Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor and HER2 status,” Annals of Oncology, 2006, doi: 10.1093/annonc/mdl016.

[11] J. Salmen et al., “Pooled analysis of the prognostic relevance of progesterone receptor status in five German cohort studies,” Breast Cancer Research and Treatment, vol. 148, no. 1, pp. 143–151, 2014, doi: 10.1007/s10549-014-3130-4.

[12] E. M. Azzato et al., “Prevalent cases in observational studies of cancer survival: Do they bias hazard ratio estimates,” British Journal of Cancer, 2009, doi: 10.1038/sj.bjc.6605062.

[13] M. Elwood et al., “A New Predictive Model for Breast Cancer Survival in New Zealand: Development, Internal and External Validation, and Comparison With the Nottingham Prognostic Index,” Journal of Global Oncology, vol. 4, no. Supplement 2, pp. 227s–227s, 2018, doi: 10.1200/jgo.18.91800.

[14] E. R. DeLong, D. M. DeLong, and D. L. Clarke-Pearson, “Comparing the Areas under Two or More Correlated Receiver Operating Characteristic Curves: A Nonparametric Approach,” Biometrics, vol. 44, no. 3, p. 837, Sep. 1988, doi: 10.2307/2531595.
[15] S.-W. Loh, M. Rodriguez-Miguelez, P. Pharoah, and G. Wishart, “A comparison of chemotherapy recommendations using Predict and Adjuvant models,” *European Journal of Surgical Oncology (EJSO)*, vol. 37, no. 5, pp. S21–S22, May 2011, doi: 10.1016/j.ejso.2011.03.082.

[16] K. Collett, F. Hartveit, R. Skjærven, and B. O. Mæhle, “Prognostic role of oestrogen and progesterone receptors in patients with breast cancer: Relation to age end lymph node status,” *Journal of Clinical Pathology*, 1996, doi: 10.1136/jcp.49.11.920.

[17] K. Collett, B. O. Mæhle, R. Skjærven, and T. Aas, “Prognostic role of oestrogen, progesterone and androgen receptor in relation to patient age in patients with breast cancer,” *Breast*, 1996, doi: 10.1016/S0960-9776(96)90055-7.

[18] M. Stendahl, L. Rydén, B. Nordenskjöld, P. E. Jönsson, G. Landberg, and K. Jirström, “High progesterone receptor expression correlates to the effect of adjuvant tamoxifen in premenopausal breast cancer patients,” *Clinical Cancer Research*, 2006, doi: 10.1158/1078-0432.CCR-06-0248.

[19] C. H. Lin *et al.*, “Fractionated evaluation of immunohistochemical hormone receptor expression enhances prognostic prediction in breast cancer patients treated with tamoxifen as adjuvant therapy,” *Journal of Zhejiang University: Science B*, vol. 11, no. 1, pp. 1–9, Jan. 2010, doi: 10.1631/jzus.B0900295.

[20] M. Abubakar *et al.*, “Combined quantitative measures of ER, PR, HER2, and KI67 provide more prognostic information than categorical combinations in luminal breast cancer,” *Modern Pathology*, vol. 32, no. 9, pp. 1244–1256, Sep. 2019, doi: 10.1038/s41379-019-0270-4.